VANCOUVER, May 15 /CNW/ - Protox Therapeutics Inc. (TSX:PRX), a leader in
the development of receptor targeted fusion proteins, today announced the
enrolment and successful dosing of the first patient in a Phase 2 clinical
trial evaluating PRX302 to treat benign prostatic hyperplasia (BPH), or
enlarged prostate, a common and bothersome urological condition that affects
over 1 million men in Canada and over 50 million men worldwide.
